Skip to main content
TipRanks
Go Ultimate75% OFF

Ovation Science (0VH) AI Stock Analysis

0 Followers
DE:0VH

Ovation Science

(Frankfurt:0VH)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Focused topical-product modelA focused product model gives the company a clear commercial direction in topical personal care and skin health. Concentrating resources on a defined application area can support disciplined product development and brand positioning over the next several quarters.
Negative Factors
Persistent unprofitabilityPersistent losses and a return to negative gross profit indicate that the current business model has not established stable unit economics. Without sustained gross margins, revenue growth is less likely to convert into earnings and the company may struggle to fund development internally.

Ovation Science (0VH) vs. iShares MSCI Germany ETF (EWG)

-60%-40%-20%0%20%40%DE:0VH-35.29%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 288.31K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-1.1
Beta (1Y)
1.02
Revenue Growth
-16.62%
EPS Growth
-27.91%
Country
Germany
Employees
5
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Ovation Science Business Overview & Revenue Model

Company Description

Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical and...

Ovation Science Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:0VH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS53NeutralCAD 29.90M-10.00-13.79%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:VEXTTSE:VEXT45NeutralCAD 50.78M-1.59-31.34%―9.88%0.18%
TSE:OILSTSE:OILS43NeutralCAD 3.40M-2.19-43.92%―-18.30%-397.37%
TSE:ATLETSE:ATLE42NeutralCAD 46.62M-0.76-2099.75%―-96.13%88.13%
TSE:BNXTTSE:BNXT39UnderperformCAD 38.11M-3.38117.02%―――

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%DE:0VHTSE:ATLETSE:LABSTSE:OILSTSE:VEXTTSE:BNXTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:0VH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:0VHOvation Science 0.01-0.01-35.29%
TSE:ATLEWillow Biosciences0.10-0.08-44.12%
TSE:LABSMedipharm Labs (Otc)0.07-0.01-7.14%
TSE:OILSNextleaf Solutions 0.02-0.04-63.64%
TSE:VEXTVext Science0.20-0.05-18.00%
TSE:BNXTBionxt Solutions Inc0.28-0.44-61.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.